Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

US: Supreme Court hears oral arguments in Mayo v Prometheus (Patently-O) (Patently-O) (Maier & Maier) (Patently-O) (Pharma Patents) (Patently-O) (Ars Technica)

US: Plaintiffs file petition for certiorari in AMP v. USPTO (Patent Docs) (Inventive Step) (Patently-O)

Januvia (Sitagliptin) – EU: Court of Justice gives go-ahead to negative term SPCs: Case C-125/10 Merck Sharp & Dohme Corporation (The SPC Blog) (The SPC Blog) (The SPC Blog) (EPLAW)

Crestor (Rosuvastatin) – US: CAFC: You don’t have to understand why your invention works: Teva v AstraZeneca (PatLit) (Patent Law Practice Center) (Patent Docs)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

2011 drug patent expirations (Patent Quality Matters)

Drugs for infectious diseases, funding and opportunity (profitability through simplicity)

WIPO patent committee: Statement of Group B (industrialized countries) at WIPO on discussions of patents and health (KEI)

WIPO Standing Committee on the Law of Patents: Obama Administration’s proposal on patents and health (KEI)

Katonomics 6: the Economics of IP in pharmaceuticals (IPKat)

Brazil: Counterfeits not just CDs and DVDs (IP tango)

EU: CJEU rules against in-transit seizures by Custom officials – good news for Indian generic companies and their consumers (Spicy IP)

EU: After Medeva: what the commentators say… (The SPC Blog)

India: The debate on copyright for DNA sequences finally put to rest?: The Delhi High Court’s verdict in Emergent Genetics India Pvt. Ltd. v. Shailendra Shivam and Ors. (Spicy IP)

US: Plaintiffs file petition for certiorari in AMP v. USPTO (Patent Docs) (Inventive Step) (Patently-O)

US: Supreme Court struggles with the patent-eligibility of personalized medicine claims: Mayo Collaborative v Prometheus (Pharma Patents) (Patently-O) (Ars Technica)

US: SCOTUS hears oral arguments in Mayo v Prometheus (Patently-O) (Patently-O) (Maier & Maier) (Patently-O)

US: SCOTUS ready for oral argument in Mayo v Prometheus, Caraco v Novo Nordisk and Kappos v Hyatt (PatLit) (Patent Docs)

US: FDA proposes generic drug user fee system and performance goals (FDA Law Blog)

US: Pending DESI program proceedings – the list (FDA Law Blog)

US: NIH licensing efforts target start-ups (BIOtechNOW)

 

Products

Atelvia (Risedronate) – US: Warner Chilcott files patent infringement complaint against Teva following Para IV certification filing (Patent Docs)

Cetuximab / Irinotecan – EU: CJEU: Question answered by Medeva, delivers Reasoned Order in Case C‑518/10, Yeda Research v Comptroller General of Patents, Designs and Trade Marks (The SPC Blog)

Crestor (Rosuvastatin) – US: CAFC: You don’t have to understand why your invention works: Teva v AstraZeneca (PatLit) (Patent Law Practice Center) (Patent Docs)

Doryx (Doxycycline) – US: CAFC reverses preliminary injunction in Warner Chilcott v Mylan (Patent Docs) (IPBiz)

Exelon (Rivastigmine) – UK: EWHC finds Rivastigmine patent obvious: Generics UK v  Novartis (JIPLP)

Focalin XR (Dexmethylphenidate) – US: Alkermes Pharma files patent infringement complaint against Teva in response to Para IV challenge (Patent Docs)

Focalin XR (Dexmethylphenidate) – US: Celgene files patent infringement complaint against Teva in response to Para IV challenge (Patent Docs)

Glivec (Imatinib) – India: Rustling section 3(d) in the Novartis case (India Patent)

Humira (Adalimumab) – India: Dealing with frivolous pre-grant oppositions with detectives (Spicy IP)

Januvia (Sitagliptin) – EU: Court of Justice gives go-ahead to negative term SPCs: Case C-125/10 Merck Sharp & Dohme Corporation (The SPC Blog) (The SPC Blog) (The SPC Blog) (EPLAW)

Ketonal (Ketoprofen) – Poland: KETONAL v KETOGEL (Class 46)

Lyrica (Pregabalin) – US: Pfizer and others file patent infringement suit against Alembic in response to Para IV challenge (Patent Docs)

Nexavar (Sorafenib) – India: Some thoughts on whether presumptive data or statistical data taken from secondary sources are sufficient to make prima facie case for compulsory license (Patent Circle)

Niaspan (Niacin) – US: Abbott files patent infringement suit against Sun Pharmaceutical in response to Para IV certification (Patent Docs)

Promethazine hydrochloride – China: NDRC fines Weifang Shuntong Pharmaceutical  and Weifang Huaxin Pharmaceutical Trading Co. for Anti-Monopoly Law violations (China Law Insight)

Tricor (Fenofibrate) – US: Abbott files patent infringement complaint against Wockhardt in response to Para IV certification (Patent Docs)

Tricor (Fenofibrate) – US: Alkermes Pharma files patent infringement suit against Wockhardt in response to Para IV certification filing (Patent Docs)

Yasmin (Drospirenone, Ethinyl estradiol) – EU: Clinical trial invalidates european patent (Pharma Patents)

Zymaxid (Gatifloxacin) – US: Senju files patent infringement complaint against Apotex in response to ANDA submission (Patent Docs)